Somatic treatment of bipolar disorder in children and adolescents

Child and Adolescent Psychiatric Clinics of North America

Volumn 11, Issue 3, 2002, Pages 595-617

  Weller, Elizabeth B ^a   Danielyan, Arman K ^b   Weller, Ronald A ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; LAMOTRIGINE; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; XANTHINE; ANTIDEPRESSANT AGENT;

ADOLESCENT; CHILD; CHILD PSYCHIATRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG PREFERENCE; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREMOR; BIPOLAR DISORDER; METHODOLOGY; PSYCHIATRIC TREATMENT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CHILD; ELECTROCONVULSIVE THERAPY; HUMAN; PSYCHIATRIC SOMATIC THERAPIES; HUMANS;

EID: 0036025235     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-4993(02)00004-4     Document Type: Review

References (167)

1. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder
2. Lithium and tricyclic antidepressants
3. Lithium carbonate use in children and adolescents: A survey of the literature
4. Treatment of bipolar disorder in children and adolescents
5. Bipolar children and adolescents: Controversies in diagnosis and treatment
6. Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: A naturalistic study
7. Lithium in hospitalized children at 4 and 8 weeks: Mood, behavior and cognitive effects
8. Lithium treatment of manic episodes with psychotic features in prepubertal children
9. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency
10. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder
11. Ethnicity and psychopharmacology. Bridging the gap
12. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study
13. Treatment of manic illness with lithium carbonate
14. The treatment of manic psychoses by the administration of lithium salts
15. Relation of serum valproate concentration to response in mania
16. Efficacy of divalproex vs lithium and placebo in the treatment of mania
17. Untoward effects of lithium treatment in children aged four through six years
18. Lithium in the treatment of a cryptogenetic psychosis in a juvenile
19. Lithium-induced behavior changes in children with symptoms suggesting manic-depressive illness
20. Lithium in children of lithium-responding parents
21. Long-term experience with lithium treatment in childhood: Correlation with clinical diagnosis
22. Check to see if these outside brackets are right [Lu 5-003 in antidepressive therapy. A controlled clinical trial with simultaneous measurement of pharmacokinetic parameters
23. Mania in childhood. II. Therapeutic trial of lithium carbonate and further description of manic-depressive illness in children
24. Manic-depressive illness in early adolescence. A study of clinical and diagnostic characteristics in six cases
25. Bipolar affective psychosis with onset before age 16 years: Report of 10 cases
26. Lithium and the treatment of adolescent manic depressive illness
27. A family study of bipolar I disorder in adolescence. Early onset of symptoms linked to increased familial loading and lithium resistance
28. Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study
29. Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children
30. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder
31. Lithium treatment of impulsive behavior in children
32. Lithium
33. Effective management with lithium of a persistent, posttraumatic hypomania in a 10-year-old child
34. Effect of tricyclic antidepressants on switching to mania and on the onset of bipolarity in depressed 6-to 12-year-olds
35. Practice guideline for the treatment of patients with bipolar disorder
36. NIMH workshop report on treatment of bipolar disorder
37. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency
38. Mania in adolescence
39. A rating scale for mania: Reliability, validity and sensitivity
40. Update on lithium carbonate therapy in children and adolescents
41. Lithium dosage guide for prepubertal children: A preliminary report
42. Comparison of lithium dosage methods for preschool- and early school-age children
43. Children's 24-hour serum lithium level after a single dose predicts initial dose and steady-state plasma level
44. The 24-hour serum lithium level as a prognosticator of dosage requirements
45. Extended survival of patients on long-term lithium treatment
46. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness
47. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients
48. Prophylactic lithium treatment of unipolar and bipolar manic-depressive illness
49. Lithium treatment in Aarhus. 2. Risk of renal failure and of intoxication
50. Complex and rapid-cycling in bipolar children and adolescents: A preliminary study
51. Mixed mania: Diagnosis and treatment
52. Bipolar I: A five-year prospective follow-up
53. Child and adolescent bipolar disorder: A review of the past 10 years
54. Recovery and relapse in adolescents with bipolar affective illness: A five-year naturalistic, prospective follow-up
55. Predictors of side effects associated with lithium administration in children
56. Renal function in children receiving long-term lithium prophylaxis
57. Side effects associated with lithium and placebo administration in aggressive children
58. Lithium, bone and body weight studies in long-term lithium-treated patients and in the rat
59. Bipolar disorder
60. Side effects associated with lithium therapy
61. Lithium: Long-term effects on the kidney. A prospective follow-up study ten years after kidney biopsy
62. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children
63. Antidysthymic drugs (antidepressants and antimanics)
64. The mania rating scale: Can it be used in children? A preliminary report
65. Episode sequence in bipolar disorder and response to lithium treatment
66. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder
67. Dysphoric mania. Clinical and biological correlates
68. Lithium in child and adolescent psychiatry
69. Adolescent bipolar illness and personality disorder
70. Pharmacokinetics of lithium carbonate in children
71. Tubular function by lithium clearance, plasma amino acids and hormones following a meat meal in childhood
72. Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines
73. Valproate in the treatment of acute mania. A placebo-controlled study
74. The naturalistic prospective course of juvenile bipolar illness
75. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: Anti-convulsant mood stabilizers and antipsychotics
76. Open trial of valproate in the treatment of adolescent mania
77. Verapamil and valproic acid treatment of prolonged mania
78. Valproic acid for the treatment of children with mental retardation and mood symptomatology
79. Valproic acid for dysphoric mania in a mentally retarded adolescent
80. Safety review of adult clinical trial experience with lamotrigine
81. Divalproex sodium treatment in late adolescent and young adult acute mania
82. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: An open clinical trial
83. Prediction of steady-state verapamil plasma concentrations in children and adults
84. Practitioner review: Electroconvulsive therapy in adolescents
85. Attention deficit hyperactivity disorder in adolescent mania
86. Divalproex treatment of disruptive adolescents: A report of 10 cases
87. Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients
88. Predictors of response to mood stabilizers
89. Epilepsy
90. Valproic acid hepatic fatalities. III. U.S. experience since 1986
91. Divalproex sodium: Migraine treatment and monitoring
92. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
93. Obesity and endocrine disorders in women taking valproate for epilepsy
94. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy
95. Mood stabilizers in children and adolescents
96. Mania and neuropsychiatric excitation following carbamazepine
97. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report
98. The place of anticonvulsant therapy in bipolar illness
99. Carbamazepine in the prophylaxis of mood disorders
100. Polypharmacy in bipolar I disorder
101. Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study
102. Carbamazepine in pediatric psychiatry
103. Carbamazepine in hospitalized aggressive conduct disorder children: An open pilot study
104. Lithium-resistant adolescent mania
105. Case study: Carbamazepine treatment of juvenile-onset bipolar disorder
106. The use of anticonvulsants in manic-depressive illness
107. Correlates of antimanic response to carbamazepine
108. Medications for aggressiveness
109. Antiepileptics (anticonvulsants)
110. Psychological effects of sodium valproate and carbamazepine in epilepsy
111. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder
112. Lamotrigine in rapid-cycling bipolar disorder
113. Lamotrigine treatment of refractory bipolar disorder
114. Suspected lamotrigine-induced toxic epidermal necrolysis
115. Lamotrigine-induced rash in children
116. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal)
117. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
118. Safety of long-term lamotrigine in epilepsy
119. New antiepileptic drugs
120. Gabapentin in bipolar disorder
121. Gabapentin in the treatment of bipolar disorder
122. Acute treatment of bipolar depression with gabapentin
123. Gabapentin associated with aggressive behavior in pediatric patients with seizures
124. Behavioral side effects of gabapentin in children
125. Lithium carbonate and carbamazepine: An effective treatment for adolescent manic or mixed bipolar patients
126. Gabapentin in the treatment of adolescent mania: A case report
127. Gabapentin toxicity in children manifesting as behavioral changes
128. The "atypical" clinical picture of adolescent mania
129. Age of onset in bipolar affective disorder and misdiagnosis as schizophrenia
130. Age at onset and number of psychotic symptoms in bipolar I and schizoaffective disorder
131. Treatment of schizoaffective disorders
132. Advances in the treatment of mania and related disorders
133. Clozapine for treatment-refractory mania
134. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series
135. Clozapine treatment of bipolar disorder in a young adolescent
136. Myocarditis and cardiomyopathy associated with clozapine
137. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
138. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
139. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
140. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo
141. Quetiapine for refractory mania in a child
142. Treatment of refractory rapid cycling bipolar disorder with risperidone
143. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
144. Risperidone treatment of refractory acute mania
145. Risperidone treatment of bipolar disorder
146. Risperidone in the treatment of mania
147. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review
148. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children
149. Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics
150. The new antipsychotics and their therapeutic potential
151. An MRI study of adolescent patients with either schizophrenia or bipolar disorder as compared to healthy control subjects
152. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
153. Olanzapine in treatment-resistant bipolar disorder
154. Olanzapine in the treatment of adolescent acute mania: A report of seven cases
155. Mood stabilizer augmentation with olanzapine in acutely manic children
156. Open-label olanzapine treatment in five preadolescent children
157. Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients
158. Electroconvulsive therapy
159. Electroconvulsive treatment compared with lithium in the management of manic states
160. A review of ECT for children and adolescents
161. Electroconvulsive therapy in treatment-resistant bipolar youth
162. Nimodipine treatment of an adolescent with ultradian cycling bipolar affective illness
163. Nutritional properties of fish oils
164. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils
165. The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets